| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Kouwenhoven, M. B. N., et al.
(författare)
-
The formation of very wide binaries during the star cluster dissolution phase
- 2010
-
Ingår i: Monthly Notices of the Royal Astronomical Society. - : Oxford University Press (OUP). - 1365-2966 .- 0035-8711. ; 404:4, s. 1835-1848
-
Forskningsöversikt (refereegranskat)abstract
- Over the past few decades, numerous wide (> 103 au) binaries in the Galactic field and halo have been discovered. Their existence cannot be explained by the process of star formation or by dynamical interactions in the field, and their origin has long been a mystery. We explain the origin of these wide binaries by formation during the dissolution phase of young star clusters: an initially unbound pair of stars may form a binary when their distance in phase space is small. Using N-body simulations, we find that the resulting wide binary fraction in the semimajor axis range 103 au < a < 0.1 pc for individual clusters is 1-30 per cent, depending on the initial conditions. The existence of numerous wide binaries in the field is consistent with observational evidence that most clusters start out with a large degree of substructure. The wide binary fraction decreases strongly with increasing cluster mass, and the semimajor axis of the newly formed binaries is determined by the initial cluster size. The resulting eccentricity distribution is thermal, and the mass ratio distribution is consistent with gravitationally focused random pairing. As a large fraction of the stars forms in primordial binaries, we predict that a large number of the observed 'wide binaries' are in fact triple or quadruple systems. By integrating over the initial cluster mass distribution, we predict a binary fraction of a few per cent in the semimajor axis range 103 au < a < 0.1 pc in the Galactic field, which is smaller than the observed wide binary fraction. However, this discrepancy may be solved when we consider a broad range of cluster morphologies.
|
|
| 5. |
- Pedersen, N. L., et al.
(författare)
-
IGEMS: The Consortium on Interplay of Genes and Environment Across Multiple Studies
- 2013
-
Ingår i: Twin Research and Human Genetics. - : Cambridge University Press (CUP). - 1832-4274 .- 1839-2628. ; 16:1, s. 481-489
-
Tidskriftsartikel (refereegranskat)abstract
- The Interplay of Genes and Environment across Multiple Studies (IGEMS) group is a consortium of eight longitudinal twin studies established to explore the nature of social context effects and gene-environment interplay in late-life functioning. The resulting analysis of the combined data from over 17,500 participants aged 25–102 at baseline (including nearly 2,600 monogygotic and 4,300 dizygotic twin pairs and over 1,700 family members) aims to understand why early life adversity, and social factors such as isolation and loneliness, are associated with diverse outcomes including mortality, physical functioning (health, functional ability), and psychological functioning (well-being, cognition), particularly in later life.
|
|
| 6. |
|
|
| 7. |
- Venkatesan, Meera, et al.
(författare)
-
Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes : parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine.
- 2014
-
Ingår i: The American journal of tropical medicine and hygiene. - : American Society of Tropical Medicine and Hygiene. - 1476-1645 .- 0002-9637. ; 91:4, s. 833-43
-
Tidskriftsartikel (refereegranskat)abstract
- Adequate clinical and parasitologic cure by artemisinin combination therapies relies on the artemisinin component and the partner drug. Polymorphisms in the Plasmodium falciparum chloroquine resistance transporter (pfcrt) and P. falciparum multidrug resistance 1 (pfmdr1) genes are associated with decreased sensitivity to amodiaquine and lumefantrine, but effects of these polymorphisms on therapeutic responses to artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) have not been clearly defined. Individual patient data from 31 clinical trials were harmonized and pooled by using standardized methods from the WorldWide Antimalarial Resistance Network. Data for more than 7,000 patients were analyzed to assess relationships between parasite polymorphisms in pfcrt and pfmdr1 and clinically relevant outcomes after treatment with AL or ASAQ. Presence of the pfmdr1 gene N86 (adjusted hazards ratio = 4.74, 95% confidence interval = 2.29 - 9.78, P < 0.001) and increased pfmdr1 copy number (adjusted hazards ratio = 6.52, 95% confidence interval = 2.36-17.97, P < 0.001 : were significant independent risk factors for recrudescence in patients treated with AL. AL and ASAQ exerted opposing selective effects on single-nucleotide polymorphisms in pfcrt and pfmdr1. Monitoring selection and responding to emerging signs of drug resistance are critical tools for preserving efficacy of artemisinin combination therapies; determination of the prevalence of at least pfcrt K76T and pfmdr1 N86Y should now be routine.
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Bjohle, J, et al.
(författare)
-
Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial
- 2013
-
Ingår i: Breast Cancer Research and Treatment. - : Springer Verlag (Germany). - 0167-6806 .- 1573-7217. ; 139:3, s. 751-758
-
Tidskriftsartikel (refereegranskat)abstract
- The primary objective was to estimate serum thymidine kinase 1 (TK1) activity, reflecting total body cell proliferation rate including cancer cell proliferation, in women with loco regional inoperable or metastatic breast cancer participating in a prospective and randomized study. Secondary objectives were to analyze TK1 in relation to progression-free survival (PFS), overall survival (OS), therapy response and other tumour characteristics, including CA 15-3, widely used as a standard serum marker for disease progression. TK1 and CA 15-3 were analysed in 198 serum samples collected prospectively from women included in the randomized TEX trial between December 2002 and June 2007. TK1 activity was determined by the ELISA based DiviTum (TM) assay, and CA 15-3 analyses was generated with the electrochemiluminescence immunoassay Cobas Elecsys CA 15-3 II. High pre-treatment TK1 activity predicted shorter PFS (10 vs. 15 months p = 0.02) and OS (21 vs. 38 months, p andlt; 0.0001), respectively. After adjustment for age, metastatic site and study treatment TK1 showed a trend as predictor of PFS (p = 0.059) and was an independent prognostic factor for OS, (HR 1.81, 95 % confidence interval (CI) 1.26-2.61, p = 0.001). There was a trend of shortened OS for women with high CA 15-3 (p = 0.054) in univariate analysis, but not after adjustment for the above mentioned covariates. Both TK1 (p = 0.0011) and CA 15-3 (p = 0.0004) predicted response to treatment. There were statistically different distributions of TK1 and CA 15-3 in relation to the site of metastases. TK1 activity measured by DiviTum (TM) predicted therapy response, PFS and OS in loco regional inoperable or disseminated breast cancer. These results suggest that this factor is a useful serum marker. In the present material, a prognostic value of CA 15-3 could not be proven.
|
|
